JP2009523004A - 癌における新規の組成物および方法 - Google Patents

癌における新規の組成物および方法 Download PDF

Info

Publication number
JP2009523004A
JP2009523004A JP2007511043A JP2007511043A JP2009523004A JP 2009523004 A JP2009523004 A JP 2009523004A JP 2007511043 A JP2007511043 A JP 2007511043A JP 2007511043 A JP2007511043 A JP 2007511043A JP 2009523004 A JP2009523004 A JP 2009523004A
Authority
JP
Japan
Prior art keywords
cancer
protein
antibody
polypeptide
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007511043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523004A5 (enExample
Inventor
デイビッド ダブリュー． モーリス，
マーク エス． マランドロ，
アルバート レイ，
クリスティン チェ，
アリ ファタイ，
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JP2009523004A publication Critical patent/JP2009523004A/ja
Publication of JP2009523004A5 publication Critical patent/JP2009523004A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2007511043A 2004-04-30 2005-05-02 癌における新規の組成物および方法 Pending JP2009523004A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/836,956 US20090215711A1 (en) 2004-04-30 2004-04-30 Novel compositions and methods in cancer
PCT/US2005/014965 WO2005107396A2 (en) 2004-04-30 2005-05-02 Novel compositions and methods in cancer

Publications (2)

Publication Number Publication Date
JP2009523004A true JP2009523004A (ja) 2009-06-18
JP2009523004A5 JP2009523004A5 (enExample) 2009-07-30

Family

ID=35320645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007511043A Pending JP2009523004A (ja) 2004-04-30 2005-05-02 癌における新規の組成物および方法

Country Status (6)

Country Link
US (2) US20090215711A1 (enExample)
EP (1) EP1747228A4 (enExample)
JP (1) JP2009523004A (enExample)
AU (1) AU2005240070A1 (enExample)
CA (1) CA2563367A1 (enExample)
WO (1) WO2005107396A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1862803A1 (en) * 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
CN104109208A (zh) * 2007-11-14 2014-10-22 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
EP2172477A1 (en) 2008-10-06 2010-04-07 Atlas Antibodies AB Epitopes derived from SATB2 and uses thereof
CA2748990A1 (en) 2008-12-26 2010-07-01 The University Of Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
US9107892B2 (en) 2010-10-28 2015-08-18 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of a novel retrovirus in patients with benign prostatic hyperplasia
FR2984363B1 (fr) * 2011-12-20 2017-11-24 Biomerieux Sa Procede pour le diagnostic ou le pronostic in vitro du cancer du sein
WO2017062750A1 (en) * 2015-10-09 2017-04-13 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treating stargardt's disease and other ocular disorders
US12577539B2 (en) 2019-04-26 2026-03-17 The Regents Of The University Of California Cells for enhanced production of adeno-associated virus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002048395A1 (en) * 2000-12-11 2002-06-20 Biosceptre Pty Ltd P2y purinergic receptor expression for identifying preneoplastic and neoplastic states

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
US6608187B2 (en) * 2000-05-23 2003-08-19 The Rockefeller University C1 bacteriophage lytic system
WO2002068633A2 (en) * 2000-11-22 2002-09-06 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
US20030087252A1 (en) * 2000-12-22 2003-05-08 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRDM11
WO2003080808A2 (en) * 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
US7276596B2 (en) * 2003-02-25 2007-10-02 Pioneer Hi-Bred International, Inc. Promoter from maize invertase inhibitor gene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002048395A1 (en) * 2000-12-11 2002-06-20 Biosceptre Pty Ltd P2y purinergic receptor expression for identifying preneoplastic and neoplastic states

Also Published As

Publication number Publication date
US20070042385A1 (en) 2007-02-22
WO2005107396A2 (en) 2005-11-17
US20090215711A1 (en) 2009-08-27
EP1747228A4 (en) 2008-05-28
EP1747228A2 (en) 2007-01-31
CA2563367A1 (en) 2005-11-17
WO2005107396A3 (en) 2006-03-23
AU2005240070A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
AU2003299646B2 (en) Novel therapeutic targets in cancer
US20060194265A1 (en) Novel therapeutic targets in cancer
US20080039413A1 (en) Novel compositions and methods in cancer
EP2196474A2 (en) Therapeutic targets in cancer
US20050202442A1 (en) Novel therapeutic targets in cancer
US20080274467A1 (en) Novel Therapeutic Targets in Cancer
JP2007535330A (ja) 癌における新規の治療標的
WO2004058146A2 (en) Novel compositions and methods in cancer
JP2006518991A (ja) 癌における新規組成物および方法
US20040219528A1 (en) Novel therapeutic targets in cancer
EP2093233A1 (en) Novel compositions and methods in cancer
US7816076B2 (en) Therapeutic targets in cancer
US20090215711A1 (en) Novel compositions and methods in cancer
US7767387B2 (en) Therapeutic targets in cancer
EP2058408A2 (en) Therapeutic GPCR targets in cancer
EP2204376A2 (en) Novel therapeutic targets in cancer
US20060134623A1 (en) Novel compositions and methods in cancer
US20090214542A1 (en) Novel therapeutic targets in cancer
US20070281896A1 (en) Novel compositions and methods in cancer
US20070218071A1 (en) Novel therapeutic targets in cancer
JP2009524405A (ja) 癌における新規な組成物および方法

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110408